Suo Jinlong, Gan Yibo, Xie Yangli, Xu Shuqin, Wang Jianfang, Chen Di, Chen Lin, Deng Lianfu, Feng Shiqing, Han Jingdong Jackie, Jiang Qing, Lei Guanghua, Liu Peng, Luo Xianghang, Ma Xin, Qu Jing, Song Chunli, Tang Peifu, Tang Tingting, Wang Sijia, Wei Xiaochun, Wu Chengtie, Xiao Guozhi, Yang Liu, Zhang Licheng, Zhang Weiqi, Zhang Zhenlin, Liu Guang-Hui, Zhang Changqing, Pei Gang, Luo Jian, Yue Rui, Zou Weiguo
Department of Orthopedic Surgery, Institute of Microsurgery on Extremities, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
State Key Laboratory of Trauma and Chemical Poisoning, Department of Spine Surgery, Center of Orthopedics, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Life Med. 2023 Nov 22;2(6):lnad045. doi: 10.1093/lifemedi/lnad045. eCollection 2023 Dec.
The skeleton is an important structural and metabolic organ in human body, while aging is the physiological basis for degenerative skeletal diseases. China has the largest aging population in the world and faces great challenges in preventing and managing diseases related to skeletal aging. To address these challenges, the Aging China Biomarkers Consortium (ABC) has reached an expert consensus on biomarkers of skeletal aging by synthesizing the literature and insights from scientists and clinicians. The consensus provides a comprehensive assessment of biomarkers associated with skeletal aging and proposes a systematic framework that categorizes biomarkers into three dimensions, namely, functional, structural, and humoral dimensions. Within each dimension, the ABC recommended clinical and evidential research-based biomarkers for physiological aging and degenerative pathologies of the skeleton. This expert consensus aims to lay the foundation for future studies to assess the prediction, diagnosis, early warning, and treatment of diseases associated with skeletal aging, with the ultimate goal of improving the skeletal health of elderly populations in China and around the world.
骨骼是人体重要的结构和代谢器官，而衰老是骨骼退行性疾病的生理基础。中国是世界上老年人口最多的国家，在预防和管理与骨骼衰老相关的疾病方面面临巨大挑战。为应对这些挑战，中国衰老生物标志物联盟（ABC）通过综合科学家和临床医生的文献及见解，就骨骼衰老的生物标志物达成了专家共识。该共识对与骨骼衰老相关的生物标志物进行了全面评估，并提出了一个系统框架，将生物标志物分为功能、结构和体液三个维度。在每个维度内，ABC推荐了基于临床和证据研究的生物标志物，用于骨骼的生理衰老和退行性病变。这一专家共识旨在为未来评估与骨骼衰老相关疾病的预测、诊断、预警和治疗的研究奠定基础，最终目标是改善中国及全球老年人群的骨骼健康。
